Examining how gadolinium contrast agents are excreted in urine after MRI
Official title: Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations
Run by Centre Hospitalier Régional Metz-Thionville · NCT06191731 · Data updated 2026-11-12
This study is testing how well patients can get rid of gadolinium contrast agents in their urine after an MRI to help find better ways to manage waste from these substances.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Centre Hospitalier Régional Metz-Thionville Academic / other |
| Locations | 2 sites (Metz, Grand Est and 1 other locations) |
| Status | Recruiting |
| Started | April 12, 2024 |
| Main results expected | April 12, 2028 |
| Study ends | April 12, 2028 |
| Registry record updated | August 21, 2026 |
| Trial ID | NCT06191731 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old who have a prescription for an MRI with gadolinium-based contrast agents.
✕Probably not a fit
Patients with known allergies to gadolinium contrast agents, severe renal impairment, or those unable to urinate independently may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to investigate the urinary excretion kinetics of gadolinium contrast agents (Gd-CAs) used in MRI examinations. Patients who have been prescribed an MRI with Gd-CAs will provide blood and urine samples before and after the injection of the contrast agent. The goal is to assess the feasibility of recovering gadolinium from urine to prevent environmental contamination, as current wastewater treatment processes do not eliminate these compounds effectively. This research could lead to improved protocols for managing gadolinium waste in medical settings.
Why it matters
Potential benefit: If successful, this study could lead to better environmental management of gadolinium contrast agents used in MRI, reducing their impact on freshwater ecosystems.
How similar studies have gone: While the approach of recovering gadolinium from urine is novel, previous studies have highlighted the environmental concerns associated with gadolinium contrast agents, indicating a need for such research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients: * over 18 years of age * with a prescription for MRI with gadolinium-based contrast agents (Gd-CAs) injection validated by a radiologist * affiliated with a health insurance plan * have signed an informed consent form Exclusion Criteria: * Patients: * with known allergy to gadolinium-based contrast agents (Gd-CAs) * with known severe renal impairment (GFR \< 30 mL/min) * on dialysis * with urinary incontinence * with an ongoing urinary tract infection * under hydric or hydrosodic restriction * unable to urinate independently * Protected persons (under guardianship, curatorship or safeguard of justice) * Pregnant or breast-feeding women
Where it's running
-
CHR Metz-Thionville/Hopital de Mercy
Metz, Grand Est, France Recruiting -
CHR Metz-Thionville / Hopital Bel Air
Thionville, France Recruiting
Study contacts
- Principal investigator: Rémi DUPRES, MD — CHR Metz Thionville Hopital Mercy
- Study coordinator: Arpiné EL NAR, PhD
- Email: projet-recherche-clinique@chr-metz-thionville.fr
- Phone: 0033387557766
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ketogenic Diet and Alcohol Intoxication: Can ketosis affect brain function and alcohol response
This study tests whether a 4‑week ketogenic diet changes how the brain works and how the body handles alcohol in adults who drink regularly.
-
Using MRI to speed diagnosis and care for adults with acute stroke in the emergency room
We will test whether a streamlined MRI protocol helps doctors diagnose and treat adults with acute stroke faster in the emergency department.
-
Following memory decline in Alzheimer disease
This project will use 7T MRI, EEG, blood and stool samples, and memory tests to see if they can track memory decline in people over 55 with Alzheimer's disease or mild cognitive impairment.
-
Predicting recovery after thrombolysis and thrombectomy using brain scan scores
This project will see if combining standard brain imaging scores can predict 90-day recovery and vessel reopening in adults who had an acute ischemic stroke treated with clot-busting medicine and clot removal.
-
FYI on MRI: decision support to help high-risk Black and Latina women decide about screening breast MRI
This project will test whether adding a decision aid to risk assessment and nurse referral helps high-risk Black and Latina women make informed choices about screening breast MRI.
-
Exploring how gut microbiome affects brain health in Alzheimer's disease
This study is trying to see how the bacteria in our gut might affect brain health in people with Alzheimer's disease and related memory issues.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.